Clinical Trial Update: Phase 2 Study of S-1 as 2nd Line Therapy in Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating S-1 as second-line therapy for metastatic pancreatic cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• S-1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: Taiho Oncology, Inc. | Conditions: Metastatic Pancreatic Cancer | Phase 2 | Status: COMPLETED